Ipamorelin 10 mg is a synthetic, highly selective research compound growth hormone secretagogue (GHRP) supplied for laboratory research only. It acts as a ghrelin receptor agonist and is studied for its effects on growth hormone (GH) secretion in laboratory models.
Key Aspects of Ipamorelin 10 mg
- Mechanism: Ghrelin receptor agonist that triggers GH release from pituitary cells in vitro, with reported selectivity over other pituitary hormones such as cortisol and prolactin.
- Research areas: GH secretion dynamics, body composition, connective tissue and protein synthesis in preclinical models.
- Combination studies: Frequently examined alongside CJC-1295 in research on synergistic GH release.
- Format: Lyophilised (freeze-dried) powder, 10 mg per vial.
- Status: Research compound; not approved for human use.
Selective Signalling
Unlike earlier generations of growth hormone secretagogues, ipamorelin has been reported not to significantly stimulate cortisol or prolactin release, which makes it a useful reference compound for research focused on GH signalling.
Metabolic and Tissue Research
Laboratory studies have examined its influence on fat mobilisation, nutrient partitioning, protein synthesis and connective tissue (tendon and ligament) models, as well as sleep architecture and circadian GH patterns.
Quality and Storage
Each vial is synthesised to high-purity standards and supplied lyophilised to preserve the compound during transport and storage. Store in a cool, dark place, or refrigerate at 2°C to 8°C. Once reconstituted with bacteriostatic water, keep chilled and use within the recommended laboratory timeframe.
For laboratory and research purposes only. Not for human consumption, medical use, or veterinary use.
